Commercial Novo Nordisk to launch Ozempic for type 2 diabetes in US Pharmaceutical TechnologyNovo Nordisk is set to launch Ozempic, its oral GLP-1 receptor agonist pill for adults with type 2 diabetes, in the US.Metabolic & GLP-1Read full story pharminent May 4, 2026 (Last updated: May 4, 2026) Pharmaceutical Technology Novo Nordisk is set to launch Ozempic, its oral GLP-1 receptor agonist pill for adults with type 2 diabetes, in the US. Metabolic & GLP-1 Read full story Post navigation Previous: Pfizer, Arvinas join SERD club with Veppanu approvalNext: UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseases Related Stories Commercial Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrand pharminent September 14, 2026 Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026